The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/14928

Please be advised that this information was generated on 2018-02-18 and may be subject to change.
Low-Density Lipoprotein Receptor-deficient Mice Are Protected Against Lethal Endotoxemia and Severe Gram-negative Infections

Mihai G. Netea, Pierre N.M. Demacker, Bart Jan Kullberg, Otto C. Boerman,* Ineke Verschueren, Anton F.H. Stalenhoef, and Jos W.M. van der Meer

Division of General Internal Medicine, Department of Medicine and *Department of Nuclear Medicine, University Hospital Nijmegen
6500 HB Nijmegen, The Netherlands

Abstract

Lipoproteins can bind lipopolysaccharide (LPS) and decrease the LPS-stimulated production of pro-inflammatory cytokines. We investigated the effect of increased plasma concentrations of low-density-lipoproteins (LDL) on survival and cytokine production after a lethal challenge with either LPS or live Gram-negative bacteria in LDL receptor deficient mice (LDLR−/−). The LDLR−/− mice challenged with LPS had an eightfold increased LD50 when compared with the wild type controls (C57Bl/6J). While tumor necrosis factor α (TNFα) and interleukin-1 α (IL-1α) plasma concentrations were increased twofold. LDLR−/− mice had significantly lower and delayed mortality than control mice after infection with Klebsiella pneumoniae. No differences in the outgrowth of bacteria in the organs were present between the two groups, while circulating cytokine concentrations were decreased twofold in LDLR−/− mice. In contrast, the LPS-stimulated in vitro production of cytokines by peritoneal macrophages of LDLR−/− mice was significantly increased compared with controls. This increase was associated with enhanced specific binding of LPS to the macrophages of LDLR−/− mice. In conclusion, endogenous LDL can protect against the lethal effects of endotoxin and Gram-negative infection. At least part of this protection is achieved through decreased in vivo production of pro-inflammatory cytokines, in spite of increased cytokine production capacity. (J. Clin. Invest. 1996. 97:1366–1372). Key words: lipopolysaccharide • gram-negative infection • tumor necrosis factor • interleukin-1 • low-density lipoproteins.

Introduction

Mammals infected with Gram-negative bacteria may develop a severe syndrome characterized by hypotension, disseminated intravascular coagulation, and renal, hepatic and cerebral damage. Most of these deleterious effects can be mimicked by infusion of endotoxin, a lipopolysaccharide (LPS) component of the cell wall of Gram-negative bacteria (1). Binding of LPS to various receptors on leukocytes triggers the production and release of proinflammatory cytokines as tumor necrosis factor α (TNFα), interleukin-1α (IL-1α) and IL-1β. In experimental models, treatment of animals with anti-TNF antibodies attenuates the lethal effects of endotoxin or Gram-negative bacteria (2, 3). A protective effect can also be obtained by treatment with either of the natural antagonists of TNF or IL-1, soluble TNF receptors or IL-1 receptor antagonist (4, 5). Thus, these cytokines are thought to play a central role in the pathophysiology of sepsis.

Once LPS enters the circulation, initial interactions with LPS-binding protein (LBP) and lipoproteins play a critical role in subsequent stimulation of pro-inflammatory cytokine synthesis. The LPS-LBP complex is bound by CD14, the cellular receptor for LBP, and this binding stimulates macrophages to release pro-inflammatory cytokines (6, 7). Recent studies also suggest that LBP may facilitate the binding of LPS not only to CD14, but also to lipoproteins (8), either by direct action of LBP or by a two-step reaction in which LPS is first transferred to sCD14 and subsequently to HDL (9). In plasma, LPS binds to various types of lipoproteins: high-density lipoproteins (HDL) (10), low-density lipoproteins (LDL) (11), very-low-density lipoproteins (VLDL) (12) and chylomicrons (13). Formation of LPS-lipoprotein complexes greatly reduces the binding of LPS to macrophages (14, 15). In vitro, this results in decreased production and release of the pro-inflammatory cytokines TNF, IL-1 and IL-6 (16, 17), and a subsequent loss of LPS toxicity.

The potential protective effect of lipoproteins against LPS-toxicity in vivo has been investigated in recent studies. Preincubation of LPS with lipoproteins prior to injection into animals decreased the mortality (10), while the in vivo infusion of lipoproteins markedly reduced the cytokinemia and mortality after LPS administration (18). Transgenic mice that express human apolipoprotein A-1 at high levels and thus have elevated plasma HDL concentrations are protected against LPS challenge (19). In contrast, hypolipidemic mice are more sensitive to the toxic effects of endotoxin (20).

All these studies have shown a protection by lipoproteins against LPS effects, while only one recent study has reported that hyperlipoproteinemia may beneficially influence severe infections with live microorganisms (21). In a rat model of cecal ligation and puncture, infusion of exogenous chylomicrons reduced both circulating LPS and TNF concentrations and mortality. However, no data regarding the effect of endogenously elevated lipoprotein concentrations on severe infections have been reported. In the present study, we assessed the effects of a lethal LPS challenge and a lethal Gram-negative infection with Klebsiella pneumoniae in the recently developed
Animals. Homozygous C57Bl/6J mice lacking low density lipoprotein receptors (LDLR—/—) and wild-type littermates were obtained from the Jackson Laboratory (Bar Harbor, ME) as mating pairs, and bred in our local facility. For the experiments, 6–8 weeks old mice, weighing 20–25 grams, were used. The animals were fed standard lab­
chow (Hope Farms, Woerden, the Netherlands) and housed under specific pathogen-free conditions. The experiments were ap­
proved by the ethical committee on animal experiments of the Catho­
lic University Nijmegen.

Lethal endotoxinemia model. Lipopolysaccharide (LPS; Escheri­
chia coli serotype O55:B5) was obtained from Sigma Chemical Co.
(St. Louis, MO). Groups of LDLR—/— and C57Bl/6J mice were injected i.v. in the retroorbital plexus (after anesthetizing with ether) with various amounts of LPS (0.25–2.5 mg/mouse). 90 min after chal­
lenge with LPS, five animals from each group were anesthetized with ether and bled from the retroorbital plexus for measurement of TNFα circulating concentrations. Another five animals per group were bled 4 h after LPS for measurement of IL-1α and IL-1β circulating concentrations. In the remaining mice (at least 5 animals/group), survival was assessed daily for 7 d.

Lethal cytokinemia model. To investigate the role of TNF and IL-1 in the LPS-induced mortality, LDLR—/— and control mice rece­
ed a single i.v. injection of recombinant human TNFα (50 µg/mouse) (kindly provided by Dr. G. Adolf, Ernst-Boehringer Institut, Vienna, Austria), recombinant human IL-1α (10 µg/mouse) (kindly provided by Dr. P. Lomedico, Hoffmann-LaRoche, Nutley, NJ), or a combina­tion of both. Several combinations of recombinant cytokines were used in different experiments: 10 µg TNFα with 1 µg IL-1α, 20 µg TNFα with 5 µg IL-1α, and 50 µg TNFα with 20 µg of IL-1α. Sur­
vival was assessed every 12 h for 2 d.

Klebsiella pneumoniae infection. Klebsiella pneumoniae (ATCC 43816), a strain that produces a lethal infection in normal mice, was injected i.v. in the retroorbital plexus (10⁶–10⁷ CFU/mouse) into LDLR—/— and control mice (LDL 8 × 10⁵ CFU/C57Bl/6J mouse). To assess whether the same protection is obtained in a more s­
masted model of infection, K. pneumoniae 10⁶–10⁷ CFU/mouse was in­
jected intramuscularly (i.m.) (LD50 5 × 10⁵ CFU/C57Bl/6J mouse) into the left thigh muscle of the animals as described (23). Survival was assessed daily for 14 d, in groups of at least 18 (i.v. infection) or 9 animals (i.m. infection). The surviving animals were sacrificed on day 28 of infection. After 90 min and 4 h, subgroups of five mice were killed and blood was collected from retroorbital plexus for the mea­surement of cytokine concentrations. The outgrowth of the microor­
ganisms from the blood, liver, spleen and kidneys of the animals was quantified 24 h after the injection of K. pneumoniae. The organs were removed aseptically, weighed, and homogenized in sterile saline in a tissue grinder. Serial dilutions of the homogenized tissues or blood (0.1 ml) were plated on sheep blood agar, and CFU were counted after overnight incubation at 37°C.

To determine the circulating LPS concentrations, in a separate set of experiments groups of 10 LDLR—/— and control mice were in­
fected i.v. or i.m. with 10⁶ CFU K. pneumoniae as described above. 90 min and 4 h after infection, groups of five animals were anesthetized
and blood collected by intracardiac puncture into 5-ml pyrogen-free plastic vials (Falcon; Becton-Dickinson Labware, Lincoln Park, NJ) containing 25 IU of pyrogen-free heparin. The tubes were centrifuged at 200 g for 10 min and plasma was collected and stored at −70°C un­
til assay.

Ex vivo cytokine production. Resident peritoneal macrophages were harvested by rinsing the peritoneal cavity aseptically with cold PBS containing 0.38% (w/vol) sodium citrate. After centrifugation for 10 min, 1,800 rpm, at 4°C, cells were resuspended in RPMI 1640 (Dutch modification; Flow Laboratories, Irvine, UK), containing 1 mM pyruvate, 2 mM L-glutamine and 100 µg/ml gentamicin. 10⁵ cells/well were cultured in 96-well microtiter plates (Costar Corporation, Cam­
bridge, MA) in RPMI medium (final volume 200 µl), with or without LPS at a final concentration of 1 µg/ml. No plasma or serum was added to the culture medium. The supernatants were collected after 24 h of incubation at 37°C, and stored at −70°C until assay. To the re­
maining macrophages, 200 µl RPMI 1640 was added, and the cells were disrupted by three freeze-thaw cycles to determine the cell-assoc­
ated cytokine contents. The samples were stored at −70°C until cytokine measurements.

The cytokine production capacity of peritoneal macrophages was also measured after stimulation by heat-killed (100°C, 30 min) Staph­
ylococcus aureus (ATCC 25923). The suspension was washed three times in RPMI (final concentration 2 × 10⁶ CFU/ml). 100 µl susp­
sion containing 10⁴ microorganisms in RPMI were added to 10⁵ per­
toneal macrophages in 96-well microtiter plates and the cells were in­
cubated 24 h at 37°C. The samples were obtained and stored at −70°C until cytokine measurements, as described above.

Cytokine measurements. TNFα, IL-1α and IL-1β concentrations were determined using specific radioimmunoassays (RIAs) devel­
oped in our laboratory (24). Briefly, standards and samples were di­
luted in RIA-buffer (per liter: 10 mM NaHPO₄, H₂O₂; 12 mM EDTA; 1 mM sodium azide (20% w/vol); 2.5-gmm bovine serum al­
bumin fraction IV (Sigma Chemical Co., St. Louis, MO); 1 ml Triton X-100; 25 µl aprotinin solution (Trasylol, containing 10,000 inhibitor units per milliliter, Bayer BV, Mydrecht, The Netherlands) diluted with deionized water milli-Q, pH 7.4. 100 µl of an appropriate mono­
specific rabbit antisera against the respective mouse cytokine was added to 100 µl of samples and standards. After vortexing, the tubes were incubated for 24 h at 4°C, followed by addition of 100 µl of the respective 125I-labeled tracer. After 20 h, 750 µl RIA buffer containing 9% (w/vol) polyethylene-glycol 6000, and 3% (vol/vol) goat anti­
rabbit IgG was added. The tubes were incubated for 20 min at room temperature and then centrifuged at 1,500 g for 15 min. Supernatants were discarded carefully and quickly drained on absorbent paper. Re­
maining radioactivity was quantified in a gamma-counter. The radioac­tivity in control tubes (the non-specific binding activity) was sub­
tracted from samples and standards. Detection limits were between 0.02 and 0.04 ng/ml. The mean of duplicate determinations was calcu­
lated for each sample. The accuracy of the cytokine assays was deter­
mined using reference preparations: murine recombinant TNFα, IL­
1α, and IL-1β obtained from the National Institute of Biological Standards and Control (NIBSC, Hertfordshire, UK). Using various batches of tracers the bias of all cytokine-­assays was < 20%; interas­
say precision ranged between 10 and 13% depending on the concen­
rature (n = 22).

LPS measurements. Plasma samples were diluted 1/100 and 1/600 with pyrogen-free saline and heated at 75°C for 5 min before the limi­
sus assay to remove the effect of serum inhibitors. LPS was deter­
mined in platelet-rich plasma by a chromogenic limulus amoebocyte lysate assay (Endosafe Inc., Charleston, SC).

Radioactive labeling of LPS. E. coli O55:B5 LPS was labeled with tritium as described previously (25) with minor modifications. Briefly, LPS (5 mg/ml) was oxidized with sodium periodate (1.5 mg/ ml) in 50 mM acetate buffer, pH 4.0, during 24 h. The remaining peri­
date was destroyed with ethylene glycol and the LPS was buffer­
changed and concentrated in an Anion concentrator (molecular cut-off 10,000 Da). 10 mCi [3H] sodium borohydride (specific activity

Lipoproteins Protect Against Gram-negative Infections 1367
IL-1α (21 Ci/mmol) was added to the oxidized LPS (5 mg/ml) in 1 mM Tris-HCl, pH 8.0. After a 2 h incubation at room temperature, the reaction was terminated by the addition of 25 μg nonradioactive sodium borohydride. The tritiated LPS was purified on a PD-10 column (Pharmacia, Woerden, The Netherlands). Subsequently, the unincorporated 3H was removed by repeated concentration in an Amicon concentrator. Elution of the 3H-labeled LPS preparation on a PD-10 column indicated that more than 95% of the 3H-label was associated with LPS both in the fresh preparation, as well as in the preparation incubated overnight at room temperature (the temperature of the incubation in the binding studies). The specific activity of this 3H-LPS was 16,000 cpm/μg.

**Binding of radiolabeled LPS to peritoneal macrophages.** Peritoneal macrophages from LDLR−/− and C57Bl/6J mice were collected as described above, and 10⁶ peritoneal macrophages were incubated in 100 μl RPMI 1640 in 1.5 ml Eppendorf plastic cups. No plasma or serum was present in the system. Increasing amounts of [3H-LPS] (10,000–100,000 cpm) were added and the cells were incubated at room temperature for 45 min (26). Cells were spun down (2,000 g, 5 min), washed twice in 100 μl RPMI solubilized in scintillation fluid and counted in a β-counter. Nonspecific binding was determined in the presence of a large excess of nonradioactive LPS. Specific binding of LPS was defined as the difference between total and nonspecific binding.

**Determination of plasma lipids.** Cholesterol and triglycerides were determined by enzymatic methods on a Hitachi 747 analyzer.

**Statistical analysis.** Survival data were analyzed using the Kaplan-Meier log rank test (27). Differences in concentrations of cytokines and in organ counts of the microorganisms were analyzed using the Kruskall-Wallis test (28). Differences were considered significant at P < 0.05. All experiments were performed at least twice.

**Results**

**Lethal endotoxemia model.** Plasma cholesterol concentrations are presented in Table I. The total cholesterol concentrations were fourfold higher in LDLR−/− mice at all the time points tested. The plasma triglyceride concentrations differed only marginally in the two mouse strains both 90 min (0.67±0.13 vs. 0.62±0.09 mmol/liter, P > 0.05) and 4 h (0.50±0.07 vs. 0.42±0.06 mmol/liter, P > 0.05) after LPS. The survival of the LDLR−/− mice was significantly increased when compared with C57Bl/6J mice, the estimated endotoxin LD₉₀ dose being 8-times higher (P < 0.001) (Fig. 1). Mortality occurred in the first 48 h after endotoxin administration, without further mortality during the next days of the follow-up. Plasma concentrations of TNFα were significantly lower in LDLR−/− mice 90 min after LPS administration, than in control animals (1.5±0.5 vs. 3.7±0.9 ng/ml, P < 0.02) (Fig. 2). Four hours after the endotoxin challenge, IL-1α concentrations were also lower in LDLR−/− mice (60±21 vs. 106±26 pg/ml, P < 0.05), while no differences in IL-1β concentrations were detected (36±9 vs. 37±9 pg/ml, P > 0.05) (Fig. 2).

**Lethal cytokinemia model.** To investigate whether the protection to a lethal injection of endotoxin is due to decreased susceptibility to proinflammatory cytokines, mice were injected i.v. with pro-inflammatory cytokines. The administration of either 50 μg recombinant human TNFα or 10 μg IL-1α did not induce any mortality. After the administration of a combination of these cytokines, no protection by the high lipoprotein concentrations of LDLR−/− mice was observed. The mortality was 0% in both mouse strains when a combination of 10 μg of TNFα and 1 μg IL-1α was injected. When a combination of 20 μg TNFα with 5 μg IL-1α was injected the mortality was 20% in LDLR−/− mice and 33% in the C57Bl/6J mice (P > 0.05), and when a combination of 50 μg TNFα with 10 μg IL-1α was injected the mortality was 80% in LDLR−/− mice, and 91% in controls (P > 0.05). The mortality occurred exclusively during the first 48 h.

**Klebsiella pneumoniae infection.** Cholesterol concentrations during *K. pneumoniae* infection decreased in both strains of mice. However, they remained significantly higher in LDLR−/− mice than in control mice (Table I). No significant differences in triglyceride levels 90 min after infection were found between the LDLR−/− and C57Bl/6J mice (0.79±0.11 vs. 0.86±0.15 mmol/liter, P > 0.05).

**Figure 1.** Survival of LDLR−/− (●) and C57Bl/6J mice (●) after LPS challenge. Groups of at least five animals received an intravenous LPS challenge with the dosages shown on the x-axis and the outcome was recorded as percentage mortality after 48 h. LDLR−/− mice had a significantly improved survival when compared with the control animals.

**Figure 2.** Plasma cytokine concentrations in LDLR−/− (shaded columns) and control mice (black columns) after an intravenous injection with 1 mg LPS. The plasma concentrations of both TNF (90 min after the LPS challenge) and IL-1α (4 h after LPS challenge) were significantly decreased in LDLR−/− mice when compared with control mice. No differences in IL-1β plasma concentrations were detected 4 h after LPS was injected. *P < 0.05; **P < 0.02.
Table I. Plasma Cholesterol Concentrations (mmol/liter) before and after LPS Challenge and K. pneumoniae Infection in LDLR−/− and C57Bl/6J Mice

<table>
<thead>
<tr>
<th></th>
<th>LDLR−/−</th>
<th>C57Bl/6J</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before LPS</td>
<td>9.55±1.11</td>
<td>2.25±0.45*</td>
</tr>
<tr>
<td>After LPS</td>
<td>5.16±1.53</td>
<td>1.42±0.27*</td>
</tr>
<tr>
<td>4 h</td>
<td>4.10±0.69</td>
<td>1.42±0.18*</td>
</tr>
<tr>
<td>After K. pneumoniae</td>
<td>5.72±1.05</td>
<td>1.78±0.08*</td>
</tr>
<tr>
<td>4 h</td>
<td>6.27±1.16</td>
<td>1.96±0.17*</td>
</tr>
<tr>
<td>24 h</td>
<td>7.42±0.63</td>
<td>2.54±0.71*</td>
</tr>
</tbody>
</table>

LDLR−/− and control mice were challenged with LPS (1 mg/mouse) or infected i.v. with 10⁶ cfu of K. pneumoniae. Each figure represents mean±SD of five mice. *P < 0.01. **P < 0.05 (for comparison between C57Bl/6J and LDLR−/−).

Table II. Bacterial Outgrowth in the Organs of LDLR−/− and C57Bl/6J Mice 24 h after i.v. and i.m. Infection with 10⁶ CFU K. pneumoniae

<table>
<thead>
<tr>
<th></th>
<th>LDLR−/−</th>
<th>C57Bl/6J</th>
</tr>
</thead>
<tbody>
<tr>
<td>K. pneumoniae i.v.</td>
<td>Liver</td>
<td>5.78±1.09</td>
</tr>
<tr>
<td></td>
<td>Spleen</td>
<td>5.72±1.04</td>
</tr>
<tr>
<td></td>
<td>Kidneys</td>
<td>4.83±1.53</td>
</tr>
<tr>
<td></td>
<td>Blood</td>
<td>4.63±1.19</td>
</tr>
<tr>
<td>K. pneumoniae i.m.</td>
<td>Liver</td>
<td>5.50±1.08</td>
</tr>
<tr>
<td></td>
<td>Spleen</td>
<td>5.52±1.57</td>
</tr>
<tr>
<td></td>
<td>Kidneys</td>
<td>5.42±1.46</td>
</tr>
<tr>
<td></td>
<td>Blood</td>
<td>4.97±0.93</td>
</tr>
</tbody>
</table>

*The data represent mean±SD of log CFU/gram of tissue for five animals. The results do not differ significantly for the three organs and the blood tested.

Table III. LPS Circulating Concentrations (ng/mL) in LDLR−/− and C57Bl/6J Mice after i.v. and i.m. Infection with 10⁶ CFU K. pneumoniae

<table>
<thead>
<tr>
<th></th>
<th>LDLR−/−</th>
<th>C57Bl/6J</th>
</tr>
</thead>
<tbody>
<tr>
<td>K. pneumoniae i.v.</td>
<td>90 min</td>
<td>6.7 (3.9-30.5)</td>
</tr>
<tr>
<td></td>
<td>4 h</td>
<td>2.9 (1.5-4.2)</td>
</tr>
<tr>
<td>K. pneumoniae i.m.</td>
<td>90 min</td>
<td>2.3 (0.1-49.2)</td>
</tr>
<tr>
<td></td>
<td>4 h</td>
<td>13.4 (1.6-26.0)</td>
</tr>
</tbody>
</table>

*The results represent median (interval) of groups of five mice. *P < 0.05 (for comparison between LDLR−/− and C57Bl/6J mice). Total LPS plasma concentrations were detected after heating the samples, a process which liberates lipoprotein-bound LPS.
In this study we showed that LDL receptor deficient mice were protected against lethal endotoxemia as well as against severe infections with Gram-negative microorganisms, not only after acute i.v. infection, but also in a more subacute model of intramuscular infection with *Klebsiella pneumoniae*. Lipoprotein concentrations in the LDLR−/− mice are genetically elevated, due to increased IDL and LDL (22). Our approach thus differs from other models in which exogenous lipoproteins were administered to obtain hyperlipoproteinemia (19). The importance of endogenous lipoproteins in the protection against lethal endotoxemia was also observed by Feingold and colleagues (20), who reported increased LPS-clearance of lipoproteins is playing the main role in the protection of LDLR−/− mice during *K. pneumoniae* infection. The LPS concentrations tended to be lower in LDLR−/− mice than in controls when the infection was induced by i.v. injection of *K. pneumoniae*. This may be due to increased LPS clearance, since we determined the LPS concentrations after heating the plasma before the assay, a procedure which liberates lipoprotein-bound LPS (31). However, in the i.m. *K. pneumoniae* infection model, the LPS concentrations were similar in the LDLR−/− and control mice. Since LDLR−/− mice in this model also showed decreased circulating cytokines, as well as decreased mortality concentrations of cytokines. The crucial role of cytokines in the response to a Gram-negative infection, independently of the bacterial load, has also been documented in our previous studies (29, 30).

The protection against the LPS component of Gram-negative bacteria by lipoproteins is achieved either by direct neutralization of LPS by forming LPS-lipoprotein complexes (8, 9, 10), or by accelerating the clearance of LPS by lipoproteins (11). In this respect, we considered if in our study an increased LPS clearance was involved. The LPS concentrations were similar in the LDLR−/− and control mice. Since LDLR−/− mice in this model also showed decreased circulating cytokines, as well as decreased mortality concentrations of cytokines. The crucial role of cytokines in the response to a Gram-negative infection, independently of the bacterial load, has also been documented in our previous studies (29, 30).

The protection against the LPS component of Gram-negative bacteria by lipoproteins is achieved either by direct neutralization of LPS by forming LPS-lipoprotein complexes (8, 9, 10), or by accelerating the clearance of LPS by lipoproteins (11). In this respect, we considered if in our study an increased LPS clearance was involved. The LPS concentrations were similar in the LDLR−/− and control mice. Since LDLR−/− mice in this model also showed decreased circulating cytokines, as well as decreased mortality concentrations of cytokines. The crucial role of cytokines in the response to a Gram-negative infection, independently of the bacterial load, has also been documented in our previous studies (29, 30).

The protection against the LPS component of Gram-negative bacteria by lipoproteins is achieved either by direct neutralization of LPS by forming LPS-lipoprotein complexes (8, 9, 10), or by accelerating the clearance of LPS by lipoproteins (11). In this respect, we considered if in our study an increased LPS clearance was involved. The LPS concentrations were similar in the LDLR−/− and control mice. Since LDLR−/− mice in this model also showed decreased circulating cytokines, as well as decreased mortality concentrations of cytokines. The crucial role of cytokines in the response to a Gram-negative infection, independently of the bacterial load, has also been documented in our previous studies (29, 30).
compared with control mice, we conclude that probably the main mechanism of protection of LDLR−/− mice in K. pneumoniae infection is through direct binding and neutralization of LPS by lipoproteins, rather than increased clearance of endotoxin. This is not surprising since the clearance of LDL, which is the main lipoprotein fraction increased in the LDLR−/− mice, is decreased in these mice (22), due to the lack of the receptor.

The increased cytokine concentrations in the circulation during Gram-negative infections are thought to be induced by the LPS component of the cell wall. We have shown that LDLR−/− mice were more LPS tolerant, the LPS LD50 in LDLR−/− mice being increased approximately eightfold. Associated with the increased protection of LDLR−/− mice we observed decreased concentrations of the pro-inflammatory cytokines TNFα and IL-1α. The LDLR−/− mice were not protected against a lethal injection of these cytokines, arguing against a direct inactivation of circulating cytokines by lipoproteins, and against decreased peripheral sensitivity of LDLR−/− mice to TNFα or IL-1. This confirms that the protection of LDLR−/− mice in lethal endotoxemia is due to an inactivation of the bacterial LPS by increased plasma lipoproteins, which in turn results in a blunted response of the pro-inflammatory cytokines.

An interesting observation was made when we evaluated the in-vitro cytokine production capacity of the LDLR−/− mice. We showed that, in contrast to the in-vivo decreased cytokine production after LPS challenge, the in-vitro LPS-stimulated cytokine production capacity of peritoneal macrophages of mice with hypercholesterolemia was higher than in control mice. This increase was observed for all the cytokines tested: TNFα, IL-1α and IL-1β. An explanation for these findings could be up-regulation of LPS receptors on the macrophages of LDLR−/− mice. Indeed, our LPS-binding experiments showed increased specific binding of trinitiated LPS to the macrophages of LDLR−/− mice. In normal mice, exposure to small LPS quantities may down-regulate its own receptors on the host cells, as has been shown for the CD14 molecule on human macrophages (32). We hypothesize that in the LDLR−/− mice, such down-regulation of LPS receptors may not occur because the enhanced plasma lipoproteins rapidly bind and neutralize the circulating endotoxin. In our experiments, stimulation with S. aureus did not induce an enhanced cytokine production by the macrophages of LDLR−/− mice, suggesting a selective down-regulation of LPS-receptors. Still, a direct effect of the high lipoprotein concentrations on the LPS receptors and LPS binding cannot be excluded, since others have shown that cholesterol modulates CD14 expression on human cells (33), and the clustering of other glycoprophospholipid-anchored receptors (34). Because LPS binds not only to CD14, but also to CD11b/CD18, to the scavenger receptor, and possibly other membrane proteins, it remains to be elucidated which of these receptors and mechanisms contributed to the increased LPS binding.

An increased cytokine production capacity has also been observed in monocytes of patients with familial hypercholesterolemia (35) and in individuals with high plasma HDL concentrations (36). The results of these studies and our present findings argue for a more general phenomenon of increased cytokine production by monocytes/macrophages of hosts with high circulating lipoprotein concentrations. The clinical importance of this phenomenon remains to be further studied.

Acknowledgments

The authors thank Dr. Robert Sauerwein and Jeanette Mulder for performing the endotoxin determinations, and Margo van den Brink, Monique Bakker and Piet Spaan for their excellent assistance with the animal experiments.

References


36. Eggesbo, J.B., I. Hjermann, P.K. Lund, G.B. Joo, R. Ovstbo, and P. Kierulf. 1994. LPS-induced release of IL-1, IL-6, IL-8, TNFα and sCD14 in whole blood and PBMC from persons with high or low levels of HDL-lipoprotein. Cytokine. 6:521-529.